Suchergebnisse - "Lindegaard, Hanne"

PubPharm (28)

1

Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission : 5-year follow-up of the IMAGINE-RA randomised trial

enthalten in: RMD open | 2024

von Møller-Bisgaard, S. | Hørslev-Petersen, K. | Ørnbjerg, L. | +18

2

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

enthalten in: Annals of the rheumatic diseases | 2023

von Østergaard, M. | van Vollenhoven, R. | Rudin, A. | +96

3

Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission

enthalten in: Rheumatology (Oxford, England) | 2021

von Møller-Bisgaard, S. | Georgiadis, S. | Hørslev-Petersen, K. | +24

CommentIn: Rheumatology (Oxford). 2021 Jan 5;60(1):3-4. - PMID 33175981

4

Active conventional treatment and three different biological treatments in early rheumatoid arthritis : phase IV investigator initiated, randomised, observer blinded clinical trial

enthalten in: BMJ (Clinical research ed.) | 2020

von Hetland, M. | Haavardsholm, E. | Rudin, A. | +96

5

Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al

enthalten in: Annals of the rheumatic diseases | 2020

von Glintborg, B. | Loft, A. | Omerovic, E. | +21

CommentOn: Ann Rheum Dis. 2019 Feb;78(2):192-200. - PMID 30396903

6

Response to : 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci

enthalten in: Annals of the rheumatic diseases | 2020

von Glintborg, B. | Loft, A. | Omerovic, E. | +21

CommentOn: Ann Rheum Dis. 2019 Feb;78(2):192-200. - PMID 30396903

7

To switch or not to switch : results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

enthalten in: Annals of the rheumatic diseases | 2019

von Glintborg, B. | Loft, A. | Omerovic, E. | +21

CommentIn: Ann Rheum Dis. 2020 Feb;79(2):e13. - PMID 30487149

8

Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis : The IMAGINE-RA Randomized Clinical Trial

enthalten in: JAMA | 2019

von Møller-Bisgaard, S. | Hørslev-Petersen, K. | Ejbjerg, B. | +25

CommentIn: JAMA. 2019 Feb 5;321(5):457-458. - PMID 30721278

9

Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis : a nationwide cohort study using Danish healthcare registers

enthalten in: Annals of the rheumatic diseases | 2018

von Cordtz, R. | Zobbe, K. | Højgaard, P. | +5

10

Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease : protocol for an open cohort study

enthalten in: BMJ open | 2018

von Kringelbach, T. | Glintborg, B. | Hogdall, E. | +42